3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      18F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization

      research-article
      1 , 2 , 3 , 4 , 5 , 1 , 2 , 6 , 6 , 7 , 1 , 1 , 1 , 8 , 9 , 10 , 10 , 11 , 3 , 4 , 5 , 12 , 13 , 14 , 15 , 16 , 1 , 4 , 5 , 17 , 18 , 18 , 1 , 19 , 20 , 20 , 16 , 16 , 16 , 3 , 4 , 5 , 12 , 13 , 14 , 15 , 3 , 4 , 5 , 12 , 21 , 22 , 23 , 24 , 22 , 24 , 18 , 4 , 5 , 17 , 25 , 26 , 6 , 6 , 7 , 1 , 16 ,
      Frontiers in Oncology
      Frontiers Media S.A.
      head and neck squamous cell carcinoma (HNSCC), fluorodeoxyglucose positron emission tomography (FDG PET), radiotherapy, metabolic tumor volume (MTV), standardized uptake value (SUV)

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is utilized for staging and treatment planning of head and neck squamous cell carcinomas (HNSCC). Some older publications on the prognostic relevance showed inconclusive results, most probably due to small study sizes. This study evaluates the prognostic and potentially predictive value of FDG-PET in a large multi-center analysis.

          Methods

          Original analysis of individual FDG-PET and patient data from 16 international centers (8 institutional datasets, 8 public repositories) with 1104 patients. All patients received curative intent radiotherapy/chemoradiation (CRT) and pre-treatment FDG-PET imaging. Primary tumors were semi-automatically delineated for calculation of SUV max, SUV mean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Cox regression analyses were performed for event-free survival (EFS), overall survival (OS), loco-regional control (LRC) and freedom from distant metastases (FFDM).

          Results

          FDG-PET parameters were associated with patient outcome in the whole cohort regarding clinical endpoints (EFS, OS, LRC, FFDM), in uni- and multivariate Cox regression analyses. Several previously published cut-off values were successfully validated. Subgroup analyses identified tumor- and human papillomavirus (HPV) specific parameters. In HPV positive oropharynx cancer (OPC) SUV max was well suited to identify patients with excellent LRC for organ preservation. Patients with SUV max of 14 or less were unlikely to develop loco-regional recurrence after definitive CRT. In contrast FDG PET parameters deliver only limited prognostic information in laryngeal cancer.

          Conclusion

          FDG-PET parameters bear considerable prognostic value in HNSCC and potential predictive value in subgroups of patients, especially regarding treatment de-intensification and organ-preservation. The potential predictive value needs further validation in appropriate control groups. Further research on advanced imaging approaches including radiomics or artificial intelligence methods should implement the identified cut-off values as benchmark routine imaging parameters.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository.

          The National Institutes of Health have placed significant emphasis on sharing of research data to support secondary research. Investigators have been encouraged to publish their clinical and imaging data as part of fulfilling their grant obligations. Realizing it was not sufficient to merely ask investigators to publish their collection of imaging and clinical data, the National Cancer Institute (NCI) created the open source National Biomedical Image Archive software package as a mechanism for centralized hosting of cancer related imaging. NCI has contracted with Washington University in Saint Louis to create The Cancer Imaging Archive (TCIA)-an open-source, open-access information resource to support research, development, and educational initiatives utilizing advanced medical imaging of cancer. In its first year of operation, TCIA accumulated 23 collections (3.3 million images). Operating and maintaining a high-availability image archive is a complex challenge involving varied archive-specific resources and driven by the needs of both image submitters and image consumers. Quality archives of any type (traditional library, PubMed, refereed journals) require management and customer service. This paper describes the management tasks and user support model for TCIA.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual.

            Answer questions and earn CME/CNE The recently released eighth edition of the American Joint Committee on Cancer (AJCC) Staging Manual, Head and Neck Section, introduces significant modifications from the prior seventh edition. This article details several of the most significant modifications, and the rationale for the revisions, to alert the reader to evolution of the field. The most significant update creates a separate staging algorithm for high-risk human papillomavirus-associated cancer of the oropharynx, distinguishing it from oropharyngeal cancer with other causes. Other modifications include: the reorganizing of skin cancer (other than melanoma and Merkel cell carcinoma) from a general chapter for the entire body to a head and neck-specific cutaneous malignancies chapter; division of cancer of the pharynx into 3 separate chapters; changes to the tumor (T) categories for oral cavity, skin, and nasopharynx; and the addition of extranodal cancer extension to lymph node category (N) in all but the viral-related cancers and mucosal melanoma. The Head and Neck Task Force worked with colleagues around the world to derive a staging system that reflects ongoing changes in head and neck oncology; it remains user friendly and consistent with the traditional tumor, lymph node, metastasis (TNM) staging paradigm. CA Cancer J Clin 2017;67:122-137. © 2017 American Cancer Society.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer

              Quantitative extraction of high-dimensional mineable data from medical images is a process known as radiomics. Radiomics is foreseen as an essential prognostic tool for cancer risk assessment and the quantification of intratumoural heterogeneity. In this work, 1615 radiomic features (quantifying tumour image intensity, shape, texture) extracted from pre-treatment FDG-PET and CT images of 300 patients from four different cohorts were analyzed for the risk assessment of locoregional recurrences (LR) and distant metastases (DM) in head-and-neck cancer. Prediction models combining radiomic and clinical variables were constructed via random forests and imbalance-adjustment strategies using two of the four cohorts. Independent validation of the prediction and prognostic performance of the models was carried out on the other two cohorts (LR: AUC = 0.69 and CI = 0.67; DM: AUC = 0.86 and CI = 0.88). Furthermore, the results obtained via Kaplan-Meier analysis demonstrated the potential of radiomics for assessing the risk of specific tumour outcomes using multiple stratification groups. This could have important clinical impact, notably by allowing for a better personalization of chemo-radiation treatments for head-and-neck cancer patients from different risk groups.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                08 June 2022
                2022
                : 12
                : 870319
                Affiliations
                [1] 1 Department of Radiation Oncology, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin , Berlin, Germany
                [2] 2 Berlin Institute of Health (BIH) , Berlin, Germany
                [3] 3 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden, Germany
                [4] 4 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ) Heidelberg , Germany, Germany
                [5] 5 OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden – Rossendorf , Dresden, Germany
                [6] 6 Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich , Munich, Germany
                [7] 7 German Cancer Consortium (DKTK), Partner Site Munich , Munich, Germany
                [8] 8 German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ) Heidelberg , Germany, Germany
                [9] 9 Department of Radiation Oncology, University Hospital and Medical Faculty, Eberhard Karls University Tübingen , Tübingen, Germany
                [10] 10 Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University , Xiamen, China
                [11] 11 Department of Nuclear Medicine, Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin , Berlin, Germany
                [12] 12 Institute of Radiooncology – OncoRay, Helmholtz-Zentrum Dresden - Rossendorf , Dresden, Germany
                [13] 13 National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ) , Heidelberg, Germany
                [14] 14 Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden , Dresden, Germany
                [15] 15 Helmholtz Association/Helmholtz-Zentrum Dresden - Rossendorf (HZDR) , Dresden, Germany
                [16] 16 Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf , Dresden, Germany
                [17] 17 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus , Dresden, Germany
                [18] 18 Department of Radiation Oncology, German Oncology Center, European University Cyprus , Limassol, Cyprus
                [19] 19 Radiation Oncology Department, Leon Bérard Cancer Center , Lyon, France
                [20] 20 Department of Nuclear Medicine, University Hospital , Ludwig-Maximilians-University (LMU) Munich, Germany
                [21] 21 German Cancer Research Center (DKFZ) , Heidelberg, Germany
                [22] 22 Electroradiology Department, University of Medical Sciences , Poznan, Poland
                [23] 23 Radiotherapy Department II, Greater Poland Cancer Centre , Poznan, Poland
                [24] 24 Department of Nuclear Medicine, Greater Poland Cancer Centre , Poznan, Poland
                [25] 25 Department of Nuclear Medicine, Klinikum Chemnitz gGmbH , Chemnitz, Germany
                [26] 26 Department of Head and Neck Surgery, Poznan University of Medical Sciences, Greater Poland Cancer Centre , Poznan, Poland
                Author notes

                Edited by: Shao Hui Huang, University Health Network, Canada

                Reviewed by: Patrick Veit Haibach, University Health Network (UHN), Canada; Frank Hoebers, Maastricht University Medical Centre, Netherlands

                *Correspondence: Frank Hofheinz, f.hofheinz@ 123456hzdr.de

                This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology

                Article
                10.3389/fonc.2022.870319
                9213669
                4cf51915-2339-41ac-a29c-7effee2e565e
                Copyright © 2022 Zschaeck, Weingärtner, Lombardo, Marschner, Hajiyianni, Beck, Zips, Li, Lin, Amthauer, Troost, van den Hoff, Budach, Kotzerke, Ferentinos, Karagiannis, Kaul, Gregoire, Holzgreve, Albert, Nikulin, Bachmann, Kopka, Krause, Baumann, Kazmierska, Cegla, Cholewinski, Strouthos, Zöphel, Majchrzak, Landry, Belka, Stromberger and Hofheinz

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 06 February 2022
                : 29 April 2022
                Page count
                Figures: 5, Tables: 2, Equations: 0, References: 39, Pages: 11, Words: 4250
                Funding
                Funded by: Bundesministerium für Bildung und Forschung , doi 10.13039/501100002347;
                Categories
                Oncology
                Original Research

                Oncology & Radiotherapy
                head and neck squamous cell carcinoma (hnscc),fluorodeoxyglucose positron emission tomography (fdg pet),radiotherapy,metabolic tumor volume (mtv),standardized uptake value (suv)

                Comments

                Comment on this article